Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26626156 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL31324582 | 0.91 | KDM4E (0.39) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL31324569 | 0.91 | KDM4E (0.39) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL31324499 | 0.88 | KDM4E (0.37) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL29985503 | 0.87 | TSHR (0.45) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL26626221 | 0.85 | TSHR (0.43) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL31324566 | 0.84 | ALDH1A1 (0.43) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL29986534 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL31324558 | 0.83 | ALDH1A1 (0.43) | KDM4EALDH1A1LMNAHTTTSHR | |
| SCHEMBL31555321 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | disclosed |
| EP-4013751-B1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-01-22 | — | — | EP | disclosed |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291519-B2 | 2-hydroxycycloalkane-1-carbamoyl | LGALS1, LGALS2, LGALS3 | KDM4E 3265/4885ALDH1A1 657/4885LMNA 772/4885 |
| US-20220324847-A1 | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | LGALS1, LGALS2, LGALS3 | KDM4E 3331/4885ALDH1A1 807/4885LMNA 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.